(Q47823211)

English

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

scientific article published in March 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

0 references

0 references

1 reference

based on heuristic

inferred from title

Angel M. Carcaboso

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

Rosa Maria Hernandez

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

Manuel-Elkin Patarroyo

object named as

Patarroyo ME

5

0 references

author name string

Igartua M

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

Rosas JE

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

Pedraz JL

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

22

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

11-12

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

1423-1432

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Efficacy trial of malaria vaccine SPf66 in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Immunisation of women with rubella (RA27-3) vaccine administered intranasally

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Intranasal immunization against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Can needle-free administration of vaccines become the norm in global immunization?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Regulation of antigen-specific immunoglobulin G subclasses in response to conserved and polymorphic Plasmodium falciparum antigens in an in vitro model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Lymphokine control of in vivo immunoglobulin isotype selection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Pathways and strategies for developing a malaria blood-stage vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Elevated plasma levels of IgE in Plasmodium falciparum-primed individuals reflect an increased ratio of IL-4 to interferon-gamma (IFN-gamma)-producing cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.020

7 January 2021

Identifiers

10.1016/J.VACCINE.2003.10.020

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/15063565

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47823211&oldid=1669911679"